The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …

Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Chimeric antigen receptor (CAR) T cell therapies have successfully treated hematological
malignancies. Macrophages have also gained attention as an immunotherapy owing to their …

Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of
haematological malignancies such as acute lymphoblastic leukaemia, B cell lymphoma and …

The success of chimeric antigen receptor (CAR) T cell therapy in treating several
hematopoietic malignancies has been difficult to replicate in solid tumors, in part because of …

Single-cell atlases promise to provide a 'missing link'between genes, diseases and
therapies. By identifying the specific cell types, states, programs and contexts where disease …

A major limitation of chimeric antigen receptor (CAR) T cell therapies is the poor persistence
of these cells in vivo. The expression of memory-associated genes in CAR T cells is linked to …

Approximately 60% of patients with large B cell lymphoma treated with chimeric antigen
receptor (CAR) T cell therapies targeting CD19 experience disease progression, and …

Clustered regularly interspaced short palindromic repeats (CRISPR) system provides
adaptive immunity against plasmids and phages in prokaryotes. This system inspires the …